Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sinocelltech Ltd.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged 18 to 80 years (inclusive) at the time of informed consent
Histologically or cytologically confirmed B cell neoplasm.
Phase 1: Relapsed or refractory disease after at least two prior systemic therapy.
Measurable or evaluable disease at enrollment.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
Adequate organ and bone marrow function
Life expectancy of ≥ 3 months
You may not be if
Prior treatment with bispecific antibodies targeting both CD20 and CD3
Prior treatment with antibodies targeting both PD-1/PD-L1, PD-(L)1/VEGF(R) or PD-(L)1/TGF-β
Eligible for high dose chemotherapy followed by hematopoietic stem cell transplantation (HSCT)
Known central nervous system (CNS) involvement by lymphoma
Known any major episode of active infection requiring treatment with systemic antibiotics within 2 weeks
Chemotherapy and other non-investigational antineoplastic agents within 4 weeks or 5 half-lives (whichever is shorter) prior to first SCTB35 administration
Clareo Health | SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin Lymphoma
